Ensysce Biosciences Inc

Ensysce Biosciences Inc. a clinical-stage pharmaceutical company engages in developing various prescription drugs for severe pain relief in opioid misuse abuse and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform an over-dose protection opioid prodrug technology. The company is developing PF614 a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases such as cystic fibrosis. It is also developing PF614 an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla California.